epinephrine low dose (ARS-2) / ARS Pharma - LARVOL DELTA

Survey of patients who were prescribed epinephrine nasal spray (ACAAI 2025) - "Among the 14 current users, 93% of respondents reported that they were likely to refill epinephrine nasal spray and 86% said they were satisfied with epinephrine nasal spray; no patients reported dissatisfaction. Conclusion Although access immediately after the initial launch was limited, resulting in a small number of respondents, early data suggest that patients report a positive experience."

Clinical • Immunology • Pediatrics

Low risk of ocular toxicity after unintentional exposure of epinephrine nasal spray (ACAAI 2025) - "Conclusion A single topical administration of epinephrine nasal spray (10 mg/mL) in rabbit eyes was not associated with any adverse effects, indicating a low risk of ocular toxicity. These results support the safety of epinephrine nasal spray in the event of unintentional ocular exposure and taken together with epinephrine’s use in other ocular formulations, suggest that no further nonclinical ocular studies are necessary."

Ophthalmology

Rationale for second dose of epinephrine nasal spray to the same nostril (ACAAI 2025) - "Conclusion Across multiple nasal conditions, mean epinephrine C max via repeated doses of intranasal epinephrine were comparable to or greater than repeated IM injections, suggesting that intranasal epinephrine is an effective first-line therapy for treatment of severe allergic reactions/anaphylaxis. When intranasal epinephrine was administered during rhinitis, both same and opposite nostril administration resulted in plasma epinephrine levels that were greater than IM injection, however repeated administration to the same nostril optimized absorption."

Allergic Rhinitis • Immunology • Inflammation

Effect of sniff after dosing of epinephrine nasal spray (ACAAI 2025) - "Sniffing during or after self-administration of intranasal epinephrine 2 mg resulted in plasma epinephrine concentrations that were higher than IM injection, suggesting that sniffing will not have any impact on efficacy. Regardless, patients should not be instructed to repeat dosing if the patient sniffs but to follow standard instructions and administer a second dose if symptoms do not improve."

Stability of epinephrine nasal spray under freeze thaw and extreme temperatures (ACAAI 2025) - "Conclusions Intranasal epinephrine potency was not affected by extreme temperature fluctuations (-20/-4 to 40°C/104°F) or by multiple freeze/thaw cycles and remained within specifications for potency under extreme temperature conditions after 3-months at 50°C/122°F or 6-months at 40°C/104°F. While intranasal epinephrine is unlikely to have reduced efficacy following exposure to extreme high or low temperatures that mimic real world exposures and boosting confidence in use throughout its 24 to 30-month shelf-life, patients/caregivers should always carry devices with them."

Anxiety and well-being related to intra-nasal epinephrine versus autoinjector in food allergic patients and caregivers (ACAAI 2025) - "Adults with needle-phobia (n=40) had significantly larger increase in well-being scores with IN access than EAI compared to those of adults who were not (n=160) (6.5/0.4, p<0.01). Conclusion Adult patients and caregivers expected to experience an improvement in their own anxiety or wellbeing when imagining access to nasal administration during acute episodes of severe allergic reactions."

Clinical • Food Hypersensitivity • Mood Disorders • Psychiatry

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: ARS Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Epinephrine Nasal Spray Improves Allergic Symptoms in Patients Undergoing Oral Food Challenge, Phase 3 Trial. (PubMed, J Allergy Clin Immunol Pract) - "neffy successfully treated OFC-induced anaphylaxis symptoms. The availability of a needle-free epinephrine delivery device may reduce dosing hesitancy, particularly in patients who are fearful of injections."

Journal • P3 data • Allergy • Dermatology • Food Hypersensitivity • Immunology • Movement Disorders • Pediatrics

Effects of Induced Allergic Rhinitis on Endogenous Epinephrine. (PubMed, Ann Allergy Asthma Immunol) - No abstract available

Journal • Allergic Rhinitis • Immunology • Inflammation